CORRESP 1 filename1.htm


Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center, Suite 500

100 Matsonford Rd
Radnor, PA 19087


May 13, 2020




Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

Attn: Irene Paik and Joseph McCann


Re:                             Marinus Pharmaceuticals, Inc.

Registration Statement on Form S-3 (File No. 333-237903)

Request for Acceleration of Effective Date


Ladies and Gentlemen:


Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Marinus Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3, as amended (the “Registration Statement”), and declare the Registration Statement effective as of 5:00 p.m., Eastern Daylight Time, on May 14, 2020, or as soon thereafter as possible.


Please feel free to direct any questions or comments concerning this request to Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.



Very truly yours,




Marinus Pharmaceuticals, Inc.






/s/ Edward F. Smith



Edward F. Smith



Vice President, Chief Financial Officer, Secretary and Treasurer


[Signature page to acceleration request]